In vivo Optical Properties of Normal Canine Prostate at 732 nm Using Motexafin Lutetium-mediated Photodynamic Therapy

Timothy C. Zhu, Stephen M. Hahn, Amy Kapatkin, Andreea Dimofte, Carmen E. Rodriguez, Teodor G. Vulcan, Eli Glatstein, R. Alex Hsi

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

The optical properties (absorption [μa], transport scattering [μ′s] and effective attenuation [μeff] coefficients) of normal canine prostate were measured in vivo using interstitial isotropic detectors. Measurements were made at 732 nm before, during and after motexafin lutetium (MLu)-mediated photodynamic therapy (PDT). They were derived by applying the diffusion theory to the in vivo peak fluence rates measured at several distances (3, 6, 9, 12 and 15 mm) from the central axis of a 2.5 cm cylindrical diffusing fiber (CDF). μa, and μ′s varied between 0.03-0.58 and 1.0-20 cm-1, respectively. μa, was proportional to the concentration of MLu. μ eff varied between 0.33 and 4.9 cm-1 (mean 1.3 ± 1.1 cm-1), corresponding to an optical penetration depth (δ = 1/μeff) of 0.5-3 cm (mean 1.3 ± 0.8 cm). The mean light fluence rate at 0.5 cm from the CDF was 126 ± 48 mW/cm2 (N = 22) when the total power from the fiber was 375 mW (150 mW/cm). This study showed significant inter- and intraprostatic differences in the optical properties, suggesting that a real-time dosimetry measurement and feedback system for monitoring light fluences during treatment should be advocated for future PDT studies. However, no significant changes were observed before, during and after PDT within a single treatment site.

Original languageEnglish (US)
Pages (from-to)81-88
Number of pages8
JournalPhotochemistry and Photobiology
Volume77
Issue number1
DOIs
StatePublished - Jan 2003
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Biophysics

Fingerprint Dive into the research topics of 'In vivo Optical Properties of Normal Canine Prostate at 732 nm Using Motexafin Lutetium-mediated Photodynamic Therapy'. Together they form a unique fingerprint.

Cite this